RTMP
COPY

9703283-3

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 38/19 — A1

(11) International Publication Number: WO 96/26738

(43) International Publication Date: 6 September 1996 (06.09.96)

(21) International Application Number: PCT/US96/03121

(22) International Filing Date: 1 March 1996 (01.03.96)

(30) Priority Data:
112834 — 1 March 1995 (01.03.95) — IL

(71) Applicants *(for all designated States except US)*: YEDA RESEARCH AND DEVELOPMENT CO. LTD. [IL/IL]; Weizmann Institute of Science, P.O. Box 95, 76100 Rehovot (IL). BEN-GURION UNIVERSITY OF THE NEGEV [IL/IL]; P.O. Box 653, 84105 Beer-Sheva (IL).

(71) Applicant *(for MW only)*: RYCUS, Avigail [US/IL]; 16 Kipnis Street, 76305 Rehovot (IL).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: WALLACH, David [IL/IL]; 24 Borochov Street, 76406 Rehovot (IL). KOST, Josef [IL/IL]; 54 Hashitah Street, 84965 Omer (IL). ELIAZ, Rom [IL/IL]; 46 Mivtza Horev, 84450 Beer-Sheva (IL).

(74) Agent: BROWDY, Roger, L.; Browdy and Neimark, Suite 300, 419 Seventh Street N.W., Washington, DC 20004 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: PHARMACEUTICAL COMPOSITIONS FOR CONTROLLED RELEASE OF SOLUBLE RECEPTORS

(57) Abstract

A controlled release pharmaceutical composition includes a biocompatible polymeric material, preferably polyethylene-vinyl acetate or poly(lactic-glucolic acid), having incorporated therein a soluble receptor capable of binding to its ligand and thus affecting the ligand's function. The soluble receptor is preferably the soluble form of TNFα receptor. Such compositions are for use in the treatment of disorders in which neutralization of the deleterious effects of TNFα is required.